Cardiac Science Enhances Global Sales and Marketing Team Names Key Executives for United States, Europe and South America.

Business Editors & Health/Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--April 25, 2001

Cardiac Science Inc. (Nasdaq:DFIB) announced today that it has significantly enhanced its global sales and marketing team with the addition of four new senior managers.

Kurt Lemvigh was appointed president, international operations; Mike Rice was appointed director of worldwide marketing; and Ivan Bolzani was appointed managing director for Latin America. In addition, Kenneth Gotlib was appointed director of U.S. hospital sales.

"We are focused on maximizing revenue from our recent acquisitions and on driving adoption and utilization of our core Powerheart(R) technology. These gentlemen bring us the additional sales and marketing experience and talent we will require to accomplish our growth objectives in the United States and internationally," said Raymond W. Cohen, president and chief executive officer of Cardiac Science.

"Mr. Lemvigh, Mr. Rice, Mr. Gotlib and Mr. Bolzani have collectively got cardiology-related device experience of over 80 years, including decades in the defibrillation and patient monitoring business. They thoroughly understand health-care sales and marketing and have distinguished themselves as top revenue producers and results-oriented managers prior to joining Cardiac Science."

In the newly created position of president, international operations, Lemvigh will assume overall responsibility for revenue generation, new business development and management of the international distribution network. In addition, Lemvigh will be responsible for managing the company's day-to-day operations at its Copenhagen, Denmark facility, which is being established as Cardiac Science's international headquarters for sales and service.

Lemvigh has 17 years of cardiology-related marketing and management experience in the European market. Previously, Lemvigh served as general manager of GE Medical Systems, Northern Europe, where he was responsible for GE's cardiology product line, including, cardiac MRI, ultrasound, monitoring, defibrillators, ECG products and cardiology information systems.

Prior to GE's acquisition of Marquette, Lemvigh served as Marquette-Hellige's cardiology marketing director for Europe, Middle East and Africa, and prior to that, he was the general manager of Kivex, A/S, a Danish medical distribution company.

Rice has been appointed director of worldwide marketing and will be responsible for managing Cardiac Science's global marketing team, and for developing OEM relationships with other medical device companies seeking to integrate Cardiac Science's technology into their product lines. Rice has extensive experience in the defibrillation business: from 1986 to 1998, Rice held several sales and marketing positions at Medtronic Physio-Control Corp., a leading manufacturer of external cardiac defibrillators.

During his 12 years at Physio-Control, Rice served as a product manager, sales representative and district service manager. Immediately prior to joining Cardiac Science, Rice was the vice president of marketing at Tegris Corp.

As managing director, Latin America, Bolzani will be responsible for managing Cardiac Science's network of distributors in South America, Central America, Mexico and the Caribbean. From 1976 to 2001, Bolzani was the director of Latin America and the Caribbean operations at Medtronic Physio-Control. During his 25 years at Physio-Control, he promoted the use of external defibrillators both in the hospital and in the pre-hospital setting and has worked closely with leading physicians in the Latin American medical community to introduce A.E.D.'s and the concept of public access defibrillation.

Gotlib will serve as director of U.S. hospital sales and will be responsible for leading Cardiac Science's 15 person hospital sales force as well as seven clinical education managers. Gotlib has more than 20 years of experience in selling cardiology devices and health-care technology to hospitals and physicians in the United States. Previously, Gotlib held sales management positions at ADAC Healthcare Information Systems, HBOC, Pointshare, BioAnalogics, Informedics and Brentwood Instruments.

About Cardiac Science

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary software that monitors a patient's cardiac activity, instantly detects the onset of a life-threatening heart rhythm and automatically delivers defibrillation without human intervention.

The company's proprietary technology has multiple applications, including use in external and wearable defibrillators and with standard patient monitors widely used in hospitals throughout the world. The growth of the company's installed base of devices provides a potential recurring revenue stream from the sale of proprietary disposable defibrillator electrodes.

Cardiac Science began marketing its first commercial product, the Powerheart(R) in the United States in early 2000. For more information, visit www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward-looking statements include, but are not limited to: the lifesaving potential of Cardiac Science's technology, and the generation of significant recurring revenue. Cardiac Science cautions that these statements are subject to substantial risks and uncertainties and are qualified by important factors that could cause actual results to differ materially from those reflected by the forwarding-looking statements and should not be relied upon by investors when making an investment decision. Information on these and other factors is detailed in the company's Form 10-K for the year ending Dec. 31, 2000, as amended, and other documents filed with the Securities and Exchange Commission.